LOXL2 and kidney cancer: Additionally, the results of analysis in the CPTAC dataset showed that LOXL2 protein expression had a noteworthy increase in tumor tissues of liver cancer, breast cancer, brain cancer, colon cancer, head and neck cancer, kidney cancer, lung adenocarcinoma, ovarian cancer, pancreatic ductal adenocarcinoma, and uterine cancer, compared with corresponding normal samples (Fig. 1B).